Seres president and chief executive Eric Shaff

Seres qui­et­ly dis­clos­es it has once again al­tered plans in ul­cer­a­tive col­i­tis

A month af­ter an­oth­er set­back in its plans to treat ul­cer­a­tive col­i­tis, Seres Ther­a­peu­tics qui­et­ly dis­closed it will not move for­ward with a Phase Ib tri­al.

The move, dis­closed in an SEC fil­ing Wednes­day, puts Seres in a predica­ment as the Cam­bridge, MA biotech failed with one po­ten­tial UC drug, SER-287, last Ju­ly, and again with an­oth­er ex­per­i­men­tal drug last month.

That sec­ond at­tempt, with SER-301, was safe to pro­ceed to the place­bo-con­trolled sec­ond co­hort in a Phase Ib tri­al even though out­come da­ta from the 15 pa­tients in­di­cat­ed none of them had achieved clin­i­cal re­mis­sion af­ter 10 weeks of treat­ment, Seres said on March 1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.